The effects of ERCC1 expression levels on the chemosensitivity of gastric cancer cells to platinum agents and survival in gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy

Liu, Yongping; Yang, Lifen; Qi, Qiufeng; Zhang, Yaping; Zhang, Chang‐Song; Zhu, Chang-Tai; Wang, Meihua; Pan, Yaodong

doi:10.3892/ol.2012.1096

Cited by 27 publications

(20 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Univariate analyses revealed that patients with low ERCC1 levels had longer relapse-free survival (RFS) and OS than those with high ERCC1 levels (median RFS, 18 vs 7 months, P = 0.001; median OS, 27 vs 11months, P = 0.001). It was concluded that gastric cancer patients with low levels of ERCC1 expression demonstrated a benefit from oxaliplatin-based adjuvant chemotherapy (Liu et al, 2013). In our study, the association between ERCC1 expression in tumor tissues and outcome in resected patients treated with oxaliplatin-based regimens confirms what has been described by other authors.…”

Section: Discussionsupporting

confidence: 81%

Correlation of ERCC1 expression in peripheral blood lymphocytes with outcomes of patients with gastric cancer treated with oxaliplatin-based adjuvant chemotherapy

Zhang

Wang

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Excision repair cross-complementing gene-1 (ERCC1) is a key regulatory enzyme whose expression patterns in tumor tissues are associated with survival in gastric cancer. The present study aimed to evaluate the effects of ERCC1 expression in peripheral blood lymphocytes (PBLs) on the outcome of patients with gastric cancer treated with oxaliplatin-based adjuvant chemotherapy. Tumor and PBL samples from 48 patients treated with adjuvant oxaliplatin-based chemotherapy for gastric cancer were analyzed. Immunohistochemistry was used to assess the expression of ERCC1. After a median follow-up of 18.5 months, the median disease-free survival (DFS) and overall survival (OS) were 12 and 20 months, respectively. Expression of ERCC1 was found in 72.9% (35/48), 56.3% (27/48), and 10.0% (2/20) of tumor tissues, PBLs from gastric cancer patients, and PBLs from controls, respectively. A significant 15921-15929 (2015) positive correlation between ERCC1 expression in PBL and cancer tissue was found (χ 2 = 12.098, P = 0.001, Pearson contingency coefficient = 0.502). Patients with negative expression of ERCC1 in tumor tissues had a significantly longer median DFS and median OS compared to patients with positive expression of ERCC1 (median DFS, 18 vs 10 months, P = 0.006; median OS, 30 vs 17 months, P = 0.012). In PBLs, high expression of ERCC1 was associated with decreased DFS (9 vs 18 months, P = 0.032), but not OS (16 vs 24 months, P = 0.057). Patients with gastric cancer exhibiting negative expression of ERCC1 are more likely to benefit from oxaliplatin-based adjuvant chemotherapy.

show abstract

Section: Discussionsupporting

confidence: 81%

Correlation of ERCC1 expression in peripheral blood lymphocytes with outcomes of patients with gastric cancer treated with oxaliplatin-based adjuvant chemotherapy

Zhang

Wang

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

show abstract

“…Similar to in NSCLC, ERCC1 has been found to be a negative predictive factor in a European population receiving adjuvant cisplatin-based chemotherapy after gastrectomy because ERCC1 negativity was associated with longer OS [134]. Similar results were seen in an Asian population that received adjuvant oxaliplatinbased chemotherapy [135]. Again, similar to the data seen in NSCLC, elevated ERCC1 was a positive prognostic biomarker in patients who did not receive adjuvant chemotherapy after resection and a negative predictive marker in patients who received chemotherapy after gastrectomy [136].…”

Section: Potential New Targetssupporting

confidence: 71%

How Prognostic and Predictive Biomarkers Are Transforming Our Understanding and Management of Advanced Gastric Cancer

2014

View full text Add to dashboard Cite

Background. Gastric cancer (GC) is the second leading cause of cancer death worldwide. GC is a heterogeneous disease in terms of histology, anatomy, and epidemiology. There is also wide variability in how GC is treated in both the resectable and unresectable settings. Identification of prognostic and predictive biomarkers is critical to help direct and tailor therapy for this deadly disease. Methods. A literature search was done using Medline and MeSH terms for GC and predictive biomarkers and prognostic biomarkers. The search was limited to human subjects and the English language. There was no limit on dates. Published data andunpublishedabstracts with clinicalrelevance were included. Results. Many potential prognostic and predictive biomarkers have been assessed for GC, some of which are becoming practice changing. This review is focused on clinically relevant

show abstract

“…High ERCC1 expression has been demonstrated to be associated with resistance to platinum-based chemotherapy and worse prognosis in cancer patients [20,37,38]. To this aim, we here assessed that the ERCC1 gene polymorphisms may play an analogous clinical role as predictive and prognostic factor among patients with T4 breast cancer receiving platinum-based therapy.…”

Section: Discussionmentioning

confidence: 99%

ERCC1 polymorphisms as prognostic markers in T4 breast cancer patients treated with platinum-based chemotherapy

et al. 2014

View full text Add to dashboard Cite

BackgroundPolymorphisms in the excision repair cross-complimentary group 1 (ERCC1) gene have been involved in the prognosis of various cancers. In the present study, we evaluated the prognostic role of the two most common ERCC1 polymorphisms in patients with T4 breast cancer receiving platinum-based chemotherapy.MethodsA total of 47 patients with T4 breast cancer undergoing treatment with a platinum-based regimen were collected and followed up (median 159 months; range, 42–239 months). ERCC1 C8092A (rs3212986) and T19007C (rs11615) polymorphisms were genotyped, using an automated sequencing approach. The same series was screened for BRCA1/2 mutations by DHPLC analysis and DNA sequencing.ResultsAmong the tested patients, 16 (34%) and 25 (53%) presented the 8092A (homo-zygosity A/A or heterozygosity A/C) and the 19007C (homozygosity C/C or heterozygosity C/T) genotypes, respectively. The 8092A and 19007C genotypes in ERCC1 were significantly associated with overall survival in T4 breast cancer patients treated with chemotherapy containing platinum (p-values = 0.036 and 0.004, respectively). Univariate and multivariate Cox regression analyses showed that combination of 8092A and 19007C genotypes acts as a significant prognostic factor in women with T4 breast cancer receiving platinum-based chemotherapy (p-values = 0.022 and 0.049, respectively). Two (4.3%) out of 47 cases were found to carry BRCA1/2 mutations; they presented the highest overall survival rates into the series.ConclusionsThe ERCC1 8092A and 19007C genotypes or their combination may predict a favorable prognosis in T4 breast cancer patients undergoing a platinum-based treatment. Further large-scale, prospective studies are needed to validate our findings.

show abstract

The effects of ERCC1 expression levels on the chemosensitivity of gastric cancer cells to platinum agents and survival in gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy

Cited by 27 publications

References 39 publications

Correlation of ERCC1 expression in peripheral blood lymphocytes with outcomes of patients with gastric cancer treated with oxaliplatin-based adjuvant chemotherapy

Correlation of ERCC1 expression in peripheral blood lymphocytes with outcomes of patients with gastric cancer treated with oxaliplatin-based adjuvant chemotherapy

How Prognostic and Predictive Biomarkers Are Transforming Our Understanding and Management of Advanced Gastric Cancer

ERCC1 polymorphisms as prognostic markers in T4 breast cancer patients treated with platinum-based chemotherapy

Contact Info

Product

Resources

About